Oculis Holding AG Ordinary shares (OCS) is a publicly traded Healthcare sector company. As of May 21, 2026, OCS trades at $28.72 with a market cap of $1.70B and a P/E ratio of 0.00. OCS moved -0.32% today. Year to date, OCS is +41.32%; over the trailing twelve months it is +58.58%. Its 52-week range spans $12.08 to $34.48. Analyst consensus is strong buy with an average price target of $50.83. Rallies surfaces OCS's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Oculis Elects Gregory D. Perry, Authorizes CHF80.25 Million Loss Carryforward and Equity Awards: Oculis’ 2026 AGM carried forward a CHF80.25 million loss, acknowledged a 2025 loss of CHF33.67 million and authorized a 31 million-share capital band. The board named Gregory D. Perry and approved USD2.15 million in director equity and USD18 million in executive equity awards.
| Metric | Value |
|---|---|
| Price | $28.72 |
| Market Cap | $1.70B |
| P/E Ratio | 0.00 |
| EPS | $0.00 |
| Dividend Yield | 0.00% |
| 52-Week High | $34.48 |
| 52-Week Low | $12.08 |
| Volume | 40 |
| Avg Volume | 0 |
| Revenue (TTM) | $0 |
| Net Income | $0 |
| Gross Margin | 0.00% |
6 analysts cover OCS: 0 strong buy, 6 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $50.83.